PepVax, Inc. has developed a DNA plasmid delivery system that utilizes a Trojan Horse approach, enabling patients' own cells to produce proteins, T-cells, and antibodies for the treatment of cancers, infectious, and genetic diseases. This method addresses the challenges of traditional drug manufacturing, which is often costly, time-consuming, and can lead to adverse immune reactions.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug manufacturing for cancers, infectious diseases, and genetic disorders can be costly, time-consuming, and may trigger adverse immune responses. Current delivery methods also face challenges in effectively targeting the affected cells or tissues.
Solution
PepVax is developing a DNA plasmid delivery system that leverages a "Trojan Horse" approach, enabling a patient's own cells to produce therapeutic proteins, T-cells, and antibodies. This in-vivo production aims to reduce manufacturing costs and timelines, while potentially minimizing adverse immune reactions. The platform is designed to address a range of diseases by stimulating a targeted immune response or producing necessary proteins directly within the patient's body. By utilizing the patient's own cells as bioreactors, PepVax seeks to improve the efficacy and tolerability of immunotherapies and protein replacement therapies.
Target Audience
The primary target audience includes patients with cancers, infectious diseases, and genetic disorders, as well as pharmaceutical companies seeking novel drug delivery platforms.
Features
- DNA plasmid-based delivery system for targeted in-vivo protein production.
- Elicits production of therapeutic proteins, T-cells, and antibodies by patient's own cells.
- Designed to address cancers, infectious diseases, and genetic disorders.